Key result
MYBPC3 dominates mutation load in Indian HCM patients, and double mutations lack association with worse pathophysiology.
Why the study?
The study was conducted to unravel the mutation status in sarcomeric genes in an urbanizing Pune population with HCM.
Cross-Sectional (n=60)
Yes
In an Indian cohort of HCM patients, the MYBPC3 gene demonstrated the highest mutation load, including the identification of novel mutations.
MYBPC3 may warrant priority in Indian HCM genetic panels; extends sarcomere data but leaves double-mutation effects open.
HCM is a monogenic cardiac disorder with a high risk of sudden cardiac death, heterogeneous phenotypic expression and genetic profile. HCM is expressed as autosomal dominant in fashion with the prevalence of 1:500 in the general population. The main objective of the current study was to unravel the mutation status in sarcomeric genes in urbanizing Pune population. HCM patients were recruited from Bharti hospital and Poona hospital and research centre, Pune after being screened by 2-D echocardiography. DNA was extracted from whole blood samples and PCR amplification was performed for selected exons from pre-selected genes, amplimers of >300 b.p were restriction digested and the SSCP technique was optimized for maximum result output. HCM patients shows the maximum prevalence of mitral regurgitation (23.3%) while the minimum prevalence was left auricular diameter (10%). Maximum variation spectrum was present in MYBPC3 genes as most of them were "benign" type as per Polyphen-2 tool status. Mutations in the MYH7 gene produce a prominent impact on splicing by the creation of a new SRP40 binding site (Exon Splicing Enhancer) as predicted by Human Splicing Finder 3.1. I736T mutation in the MYH7 gene results in replacement of β-strand by α-helix upstream from mutation site which may have a profound impact on protein tertiary structure as predicted by Polyphen-2 tool (probably damaging-1.00). Also, two 'novel' mutations and one 'novel' variation were reported in the present study. Thus, the MYBPC3 gene shows maximum mutation load among other sarcomeric genes. Double gene mutations do not represent much severe pathophysiology as compared to single gene mutated and genotypic negative HCM patients.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2022) conducted a cross-sectional in Hypertrophic cardiomyopathy (n=60). Genetic screening for sarcomeric gene mutations vs. Healthy controls without a family history of cardiac disorders was evaluated on Prevalence and spectrum of sarcomeric gene mutations. In an Indian population of hypertrophic cardiomyopathy patients, the MYBPC3 gene showed the maximum mutation load among sarcomeric genes, and double gene mutations did not represent a more severe pathophysiology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: